1415694-72-2

Upstream product

• 1415728-06-1 N'-(3-bromo-5-iodopyridin-2-yl)-N-hydroxyformimidamide 
• 269409-73-6 3-carboxyphenylboronic acid pinacol ester 
• 112275-50-0 tert-butyl 1,4-diazepine-1-carboxylate 
• 1415728-06-1 (E)-N'-(3-bromo-5-iodopyridin-2-yl)-N-hydroxy-formimidamide 
• 1415695-11-2 tert-butyl 4-(3-(8-(5,6-dimethoxypyridin-2-ylamino)-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)benzoyl)-1,4-diazepane-1-carboxylate 
• 1415695-10-1 tert-butyl 4-(3-(8-bromo-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)benzoyl)-1,4-diazepane-1-carboxylate 
• 1036990-37-0 tert-butyl 4-(-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)-1,4-diazepane-1-carboxylate 
• 1415314-10-1 8-bromo-6-iodo-[1,2,4]triazolo[1,5-a]pyridine 
• 697300-73-5 2-amino-3-bromo-5-iodopyridine 
• 20511-12-0 2-amino-5-iodopyridine 

Relevant academic research and scientific papers

TRIAZOLOPYRIDINE COMPOUNDS

The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

TRIAZOLOPYRIDINE COMPOUNDS

The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.